Villanueva-Meyer Javier E, Han Seunggu J, Cha Soonmee, Butowski Nicholas A
Department of Radiology and Biomedical Imaging, University of California at San Francisco, 505 Parnassus Ave, M-391, San Francisco, CA, 94117, USA.
Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA, USA.
J Neurooncol. 2017 Aug;134(1):213-219. doi: 10.1007/s11060-017-2511-z. Epub 2017 May 31.
Early tumor growth, or increased contrast-enhancing tumor not related to evolving post-surgical injury, in the interval between surgical resection and initiation of radiotherapy has implications for treatment planning and clinical outcomes. In this study we evaluated the incidence of early tumor growth, correlated tumor growth with survival outcome measures, and assessed predictors of early tumor growth in glioblastoma. We reviewed the records of patients with newly-diagnosed glioblastoma who underwent surgical resection and chemoradiotherapy at our institution. Patients with preoperative, immediate postoperative, and preradiotherapy MRI were included. Conventional MRI and DWI features were assessed. The correlation between early tumor growth and extent of resection with survival was assessed with Kaplan-Meier analysis. Logistic regression was carried out to evaluate predictors of early tumor growth. Of 140 included patients, sixty-seven cases (48%) had new or increased contrast enhancement attributed to early tumor growth. Median progression free survival (PFS) and overall survival (OS) were shorter in patients with early tumor growth compared to those without early tumor growth (p < 0.001 for both). Additionally, PFS and OS were longer in patients who underwent gross total resection of enhancing tumor (p = 0.016 and <0.001, respectively). Of the evaluated predictors of early growth, subtotal resection was most likely to result in early growth (p < 0.001). Imaging evidence of early tumor growth is often observed at preradiotherapy MRI and is associated with shorter survival. Gross total resection of contrast enhancing tumor decreases likelihood of early tumor growth.
在手术切除与放疗开始的间隔期内,早期肿瘤生长,或者与术后损伤进展无关的增强造影剂的肿瘤增加,对治疗计划和临床结果具有重要意义。在本研究中,我们评估了早期肿瘤生长的发生率,将肿瘤生长与生存结局指标相关联,并评估了胶质母细胞瘤早期肿瘤生长的预测因素。我们回顾了在我们机构接受手术切除和放化疗的新诊断胶质母细胞瘤患者的记录。纳入术前、术后即刻和放疗前进行磁共振成像(MRI)检查的患者。评估了常规MRI和扩散加权成像(DWI)特征。采用Kaplan-Meier分析评估早期肿瘤生长与切除范围和生存之间的相关性。进行逻辑回归以评估早期肿瘤生长的预测因素。在纳入的140例患者中,67例(48%)有新的或增强造影剂增加,归因于早期肿瘤生长。与无早期肿瘤生长的患者相比,有早期肿瘤生长的患者无进展生存期(PFS)和总生存期(OS)的中位数更短(两者p均<0.001)。此外,接受增强肿瘤全切术的患者PFS和OS更长(分别为p = 0.016和<0.001)。在评估的早期生长预测因素中,次全切除最有可能导致早期生长(p<0.001)。放疗前MRI常可观察到早期肿瘤生长的影像学证据,且与生存期缩短相关。增强肿瘤的全切术可降低早期肿瘤生长的可能性。